AgeichikA., BuchholzC.J., CollinsM.K.2011. Lentiviral vectors targeted to MHC II are effective in immunization. Hum. Gene Ther., 22:1249–1254.
2.
BroussauS., JabbourN., LachapelleG.et al.2008. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther., 16:500–507.
3.
BrummelkampT.R., BernardsR., AgamiR.2002. A system for stable expression of short interfering RNAs in mammalian cells. Science, 296:550–553.
4.
BushmanF., LewinskiM., CiuffiA.et al.2005. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol., 3:848–858.
5.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467:318–322.
6.
CockrellA.S., MaH., FuK.et al.2006. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther., 14:276–284.
7.
FireA., XuS., MontgomeryM.K.et al.1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391:806–811.
8.
FishR.J., KruithofE.K.2004. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol. Biol., 5:9.
FroelichS., TaiA., KennedyK.et al.2011. Pseudotyping lentiviral vectors with Aura virus envelopeglycoproteins for DCV-SIGN–mediated transduction of dendritic cells. Hum. Gene Ther., 22:1281–1291.
11.
GalimiF., SaezE., GallJ.et al.2005. Development of ecdysone-regulated lentiviral vectors. Mol. Ther., 11:142–148.
12.
Giry-LaterrièreM., CherpinO., KimY.-S.et al.2011. Polyswitch lentivectors: “All-in-one” lentiviral vectors for drug-inducible gene expression, live selection, and recombination cloning. Hum. Gene Ther., 22:1255–1267.
13.
GossenM., BujardH.1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A., 89:5547–5551.
14.
Hacein-Bey-AbinaS., GarrigueA., WangG.P.et al.2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.
15.
HoweS.J., MansourM.R., SchwarzwaelderK.et al.2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118:3143–3150.
KutnerR.H., ZhangX.Y., ReiserJ.2009. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc., 4:495–505.
20.
LiX.-Y., LaiY.-K., ZhangJ.-F.et al.2011. Lentivirus-mediated RNA interference targeting Bax inhibitor-1` suppresses ex vivo cell proliferation and in vivo tumor growth of nasopharyngeal carcinoma. Hum Gene Ther., 22:1201–1208.
21.
LizeeG., GonzalesM.I., TopalianS.L.2004. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther., 15:393–404.
22.
MatraiJ., ChuahM.K., VandendriesscheT.2010. Recent advances in lentiviral vector development and applications. Mol. Ther., 18:477–490.
23.
MertenO.W., CharrierS., LaroudieN.et al.2011. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther., 22:343–356.
24.
MeteloJ., WardN., ThrasherA.J., BurnsS.O.2011. Lentivectors are efficient tools to manipulate the dendritic cell cytoskeleton. Cytoskeleton, 68:434–445.
25.
MorizonoK., KuA., XieY.et al.2010. Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J. Virol., 84:6923–6934.
26.
OttM.G., SchmidtM., SchwarzwaelderK.et al.2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med., 12:401–409.
27.
PapadakiM., Konstantina SiapatiE., VassilopoulosG.2011. A foamy virus vector system for stable and efficient RNAi expression in mammalian cells. Hum. Gene Ther., 22:1293–1303.
28.
ParkT.S., RosenbergS.A., MorganR.A.2011. Treating cancer with genetically engineered T cells. Trends Biotechnol.Epub ahead of print10.1016/j.biotech.2011.04.009.
29.
PorterD.L., LevineB.L., KalosM.et al.2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365:725–733.
30.
SchambachA., BaumC.2008. Clinical application of lentiviral vectors: Concepts and practice. Curr. Gene Ther., 8:474–482.
31.
SchroersR., SinhaI., SegallH.et al.2000. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther., 1:171–179.
32.
SirinO., ParkF.2003. Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system. Gene, 323:67–77.
33.
SoneokaY., CannonP.M., RamsdaleE.E.et al.1995. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res., 23:628–633.
34.
SteinS., OttM.G., Schultze-StrasserS.et al.2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med., 16:198–204.
35.
ThromR.E., OumaA.A., ZhouS.et al.2009. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood, 113:5104–5110.
36.
TronoD.2000. Lentiviral vectors: Turning a deadly foe into a therapeutic agent. Gene Ther., 7:20–23.
37.
VignaE., CavalieriS., AillesL.et al.2002. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Ther., 5:252–261.
38.
XuK., MaH., McCownT.J.et al.2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther., 3:97–104.
39.
YangL., YangH., RideoutK.et al.2008. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol., 26:326–334.
40.
ZareiS., LeubaF., ArrighiJ.F.et al.2002. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. J. Allergy Clin. Immunol., 109:988–994.
